Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial
Key points are not available for this paper at this time.
Abstract
UK Research and Innovation and UK Department of Health and Social Care.
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Demander à l'IA
Like
Bookmark
Share
View Full Paper
Azithromycin for community treatment of suspected COVID-19 in people at increased risk of an adverse clinical course in the UK (PRINCIPLE): a randomised, controlled, open-label, adaptive platform trial | Synapse